Cisplatin-based combination chemotherapy is the standard treatment for metastatic non-seminomatous germ cell tumours (NSGCT) of testicular or extragonadal origin and many reports exist of successful therapy using regimens incorporating various combinations of cisplatin (DDP), vinblastine, bleomycin (BLM), etoposide (VP16), doxorubicin, cyclophosphamide and several other agents . Uniformly high rates of complete response and longterm survival are described among patients with so-called 'good prognosis' or 'minimal risk' metastatic disease (Williams et al., 1987; Newlands et al., 1986; Logothetis et al., 1986; Bosl et al., 1986) . However, the relative merits of more dose-intensive regimens claimed to produce better results in 'poor prognosis' NSGCT (Newlands et al., 1986; Logothetis et al., 1986; Daugaard & Rorth, 1986; Ozols, 1987; Schmoll et al., 1987) are difficult to interpret for two main reasons: (i) lack of uniform staging criteria or prognostic indices in published series, and (ii) improved results from older combinations as physician familiarity with DDP-based chemotherapy increased (Medical Research Council Working Party on Testicular Tumours, 1985; Einhorn, 1986) .
Traditionally, testicular cancer staging in North America has followed Samuels' M.D. Anderson Hospital system (MDA) with patients divided into minimal and advanced categories for prognostic purposes (Logothetis et al., 1986 ). Einhorn's group from Indiana University (IND) developed a three-tiered system (minimal, moderate and advanced) which appears to delineate an adverse prognosis group more accurately Williams et al., 1987) . Royal Marsden Hospital staging (RMH) separates patients into small and large volume prognostic groups and is used widely in the United Kingdom and Europe (Peckham, 1981) .
All these systems are based on site and bulk of metastatic disease judged by clinical and radiological criteria. However, Germa-Lluch et al. (1980) showed initial serum levels of tumour markers (alpha fetoprotein, aFP; human chorionic gonadotrophin, hCG) correlated with survival in patients treated for advanced NSGCT and Vugrin et al. (1984) radiological assessment of disease site and bulk plus initial serum marker (aFP, hCG) levels. At Charing Cross Hospital (CXH) we have used RMH staging in reporting our results but have also defined good and poor prognostic groups by initial marker (aFP, hCG) levels only, regardless of clinical or radiological extent of metastatic disease (Newlands et al., 1986; Begent & Bagshawe, 1983) .
Other investigators have produced prognostic equations from retrospective multiple regression analyses of pretreatment factors in patients with metastatic NSGCT (Bosl et al., 1983; Birch et al., 1986) while the European Organization for Research on Treatment of Cancer (EORTC) defined four prognostic groups using similar methods (Stoter et al., 1987 ). High initial serum hCG level appears the most important predictor of poor prognosis from these studies.
In this paper, we review 10 years' single institution experience with metastatic NSGCT treated using the POMB/ ACE regimen (Newlands et al., 1986) . All patients were reclassified according to a number of published staging and prognostic criteria aiming to define the relative value of these commonly used clinical systems in predicting long-term outcome as well as the efficacy of POMB/ACE in poor prognosis metastatic NSGCT.
Patients and methods
Records from 237 patients with metastatic testicular and extragonadal NSGCT treated between May 1977 and February 1988 were examined. All received first-line chemotherapy with the POMB/ACE regimen described previously (Newlands et al., 1986) . When this regimen was first used, only two courses of POMB (total DDP dose 240mg m2) were given but it was soon apparent that larger DDP doses were necessary to maximise response rate in advanced disease. Outcome in 31 patients who received the less intensive treatment has been reported (Newlands et al., 1986) and those patients were not included in this series, which comprises 206 consecutive cases of metastatic NSGCT treated with at least three courses of POMB (minimum DDP dose 360mg m 2) since April 1979 (for administration of POMB/ ACE chemotherapy see the Appendix). Histological diagnosis of NSGCT was made from primary lesion or metastatic deposit (British Testicular Tumour Panel, BTTP, criteria (Pugh, 1976) No patient with very advanced disease was excluded from analysis because of poor clinical condition at presentation.
All patients were assessed initially by physical examination, serum and cerebrospinal fluid levels of aFP and hCG, chest X-ray, conventional whole lung tomography or computerised tomography (CT) of thorax, plus abdominal and pelvic ultrasound and/or CT. Some patients had other investigations, including bipedal lymphography, radionuclide liver scan and CT brain.
Extent of metastatic disease at initiation of chemotherapy was used to classify our patients according to the systems of (i) MDA (Logothetis et al., 1986) (Table I ), (ii) IND Williams et al., 1987) (Table II) and (iii) RMH (Peckham, 1981) (Table III) . Extent of metastatic disease plus initial aFP and hCG were used to divide our patients into the groups proposed by (iv) the MRC Working Party on Testicular Tumours (1985) ( Table IV) . Extent of disease, initial aFP and tumour histology were used to separate our patients into prognostic groups proposed by (v) EORTC (Stoter et al., 1987) (Table V) . Based on initial markers (aFP, hCG) only, patients were classified by (vi) CXH tumour marker criteria (Newlands et al., 1986; pulmonary nodule >5 cm diameter; >5 metastases per lung field with at least one > 1 cm diameter; multiple lung nodules (>5 total) with at least one >2cm diameter; pleural effusion; hypoxia (P02 <75 mmHg); pure choriocarcinoma histology; extragonadal primary; central nervous system involvement; liver or other visceral metastases; aFP> 1,000 kU l-; hCG> 10,000 IU 1 l.
3. Schmoll et al. (1987) > 1Ocm diameter abdominal mass; >5 lung metastases with diameter >2 cm each; >20 lung metastases with diameter <2cm each; mediastinal mass >5cm diameter; visceral, bone or central nervous system metastases. 4. Pizzocaro et al. (1985) > 10cm diameter abdominal mass, >5 cm diameter pulmonary nodule; liver, bone or central nervous system involvement; aFP>l,OOOkUI-1; hCG>50,000IUl-.
believe masses of this size are palpable readily in the NSGCT population consisting mainly of young non-obese males. Para-aortic node masses were palpable in patients in this series with radiological node dimensions less than 5cm diameter.
Our patients who fulfilled the advanced disease, poor prognosis or bulky disease criteria of Daugaard & Rorth (1986) , Ozols (1987) and Schmoll et al. (1987) were identified so outcome with these authors' regimens containing ultra-high dose DDP could be compared with POMB/ACE. Reclassification according to the far advanced disease criteria of Pizzocaro et al. (1985) was performed to allow comparison with a group receiving therapy based on conventional dose DDP (100mgm-2). All these criteria are shown in Table VI. Survival curves were constructed by the method of Kaplan & Meier (1958) and compared by log rank analysis (Mantel, 1966) .
Results
Of the 206 patients, 13 were excluded from analysis because of (i) unknown initial disease parameters or incomplete staging (four patients), (ii) prior DDP-containing chemotherapy (six patients), and (iii) adjuvant chemotherapy administered after complete resection of metastatic disease in the presence of normal tumour markers (three patients).
The remaining 193 patients were fully assessable. Median age was 28 years (range 14-61). Histology (BTTP (18)) was malignant teratoma undifferentiated in 101 cases (52%), malignant teratoma intermediate in 53 (27%), malignant teratoma trophoblastic in 20 (10%), malignant teratoma differentiated in seven, seminoma in six and was unknown in six cases. Twenty patients (10%) were marker-negative but initial serum aFP was greater than 500kUl-in 35 cases (18%) and initial serum hCG greater than 50,000IU1 1 in 20 cases (10%) (Germa-Lluch et al., 1980) . Two patients with unknown histology but serum hCG in excess of 100,000 IU11 at presentation were regarded as having trophoblastic histology under the EORTC criteria (Table V) .
All causes of death were included in subsequent survival analyses and, in particular, no early deaths were excluded. Twenty-two patients have died for an overall survival of 88.6% (171/193) at median follow-up 4.1 years (range 5 days to 8.7 years). The survival in the 20 patients with extragonadal primaries was not very different from the whole group: retroperitoneal primaries 7/12 (58%) and mediastinal primaries 8/8 (100%) giving an overall survival of 15/20 (75%). A specific and intractable problem in the retroperitoneal primaries was duodenal involvement which resulted in three of the deaths. Figure 1 shows survival curves constructed after reclassification of our patients by MDA criteria, Figure Years Figure 4 Survival curves after reclassification by MRC criteria into low (n = 72), medium (n =67) and high (n = 54) risk disease. n.s., no significant difference (log rank). Years Figure 5 Survival curves after reclassification by EORTC criteria into four prognostic groups (1-4). n.s., no statistically significant difference (log rank).
received prior radiotherapy were excluded from analysis, although survival in each category was slightly better. Figure 7 shows survival curves obtained when our patients with advanced, poor prognosis, bulky or far advanced disease defined by the criteria of Daugaard & Rorth (1986) , Ozols (1987 ), Schmoll et al. (1987 and Pizzocaro et al. (1985) were compared. Ozols (1987) b. Pizzocaro etal. (1985) c. Schmoll etal. (1987) d. Daugaard & Rorth (1986) Among 22 deaths in our series, the majority were recorded in the most advanced groups under each classification system or in the poor prognostic categories defined previously. However, the size of these 'adverse prognosis' groups ranged from 54 patients including 11 deaths (MRC high risk) to 116 patients including 19 deaths (MDA advanced). Therefore, survival data were adjusted for group size with true positive (TP) in each case regarded as the fraction dying in the adverse prognosis group; true negative (TN) th 'fraction alive in the favourable prognosis (remaining patients) group; false positive (FP) the fraction alive in the adverse prognosis group; and false negative (FN) the fraction dying in the favourable prognosis group. Sensitivity and specificity of each adverse prognosis definition in predicting death were calculated (sensitivity=TP/(TP+FN) x 100%; specificity= TN/(FP+TN) x 100%). Results are shown in Table VIII . Sensitivity varied by no more than 10% (range 71-81%) and specificity by less than 5% (range 52-56%) regardless of definition of adverse prognosis and were not altered significantly if deaths from intercurrent disease were excluded.
Seven deaths (32%) were noted two years or more after commencement of first-line chemotherapy and four of these fell into adverse prognostic groups by all definitions. A fifth patient was poor prognosis by CXH criteria but favourable prognosis under the other systems. The final two were both in the MDA advanced disease group. One patient died from myocardial infarction without evidence of residual NSGCT but all other late deaths occurred in patients with relapsed Reference and regimen used survival follow-up same follow-up 1. Daugaard & Rorth (1986) 24/33 (73%) 18.5 months 59/67 (88%) DDP 40 mgm 2 x 5 days (3-weekly) VP16 200mgm-2 x 5 days (3-weekly) BLM 15 mg m -2 weekly 2. Ozols (1987) 23/30 (77%) 27 months 99/113 (88%) DDP 40 mgm2 x 5 days (3-weekly) VP16 100 mg m -2 x 5 days (3-weekly) VLB 0.2mg kg-1 (3-weekly) BLM 30mg weekly 3. Schmoll et al. (1987) 69/98 (70%) 2.2 years 59/67 (88%) DDP 35 mgm-2 x 5 days (3-weekly) VP16 120mgm2 x 5 days (3 weekly) BLM 15 mgm2 weekly 4. Pizzocaro et al. (1985) 34/40 (85%) 2 years 63/75 (84%) DDP 20 mg m 2 x 5 days (3-weekly) VP16 100mgm-2 x5 days (3-weekly) BLM 18 mg m -2 weekly (four) or persistent (two) NSGCT. Two of four relapsed patients sustained their disease recurrence more than 12 months after completing first-line treatment in complete remission. The two patients never rendered completely disease-free had unresectable mature cystic teratoma in the retroperitoneum. Active tumour, including cerebral metastases, recurred in the first of these patients two years after completion of first-line therapy and caused his demise. The second patient's disease was controlled partially by various treatments over a long period but he developed acute nonlymphoblastic leukaemia and died more than 8 years after the original diagnosis of metastatic NSGCT.
Discussion
These results imply that-a poor prognostic category can be defined in metastatic NSGCT by initial serum marker (aFP, hCG) levels alone at least as reliably as by more complicated staging systems based on clinical and radiological measurement of disease extent. The method is easy to use in clinical practice and, because these markers reflect presence of the NSGCT components of greatest lethal potential (yolk sac, aFP; trophoblast, hCG (Paradinas, 1983) , it is logical as well. Long-term survival of 100% among our markernegative patients lends further support to this conclusion. Multiple combinations and permutations of published adverse prognostic criteria Newlands et al., 1986; Logothetis et al., 1986; Bosl et al., 1986; Daugaard & Rorth, 1986; Ozols, 1987; Schmoll et al., 1987; Medical Research Council Working Party on Testicular Tumours, 1985), only some of which are described in this paper, attest to the lack of agreement on definition of advanced, bulky or poor prognosis disease. Chronologically, NSGCT deaths fall into two broad groups: (a) early, from overwhelming and rapidly progressive tumour at presentation; and (b) late, due to chemotherapy resistance. Our data suggest all commonly used definitions of adverse prognosis to have similar relatively modest sensitivity and specificity in predicting long-term outcome although early and late deaths were predicted equally. Long-term survival must remain the ultimate criterion of successful therapy in a highly responsive malignancy regardless of reported improvements in response rate. Numerically larger adverse prognostic groups (e.g. MDA: Ozols, 1987) included patients classified as good prognosis by other criteria, causing apparent 'dilution' of results.
Late death remains a problem in NSGCT, especially among poor prognosis patients. Many published series with average follow-up of two to three years cannot hope to address this (Williams et al., 1987; Logothetis et al., 1986; Daugaard & Rorth, 1986; Ozols, 1987; Schmoll et al., 1987) . Seven of 22 deaths (32%) in our series were noted two years or more from initiation of therapy and over half (12/22, 55%) occurred at more than 18 months. However, overall survival among all our patients (88.6%) is at least as good as any other published series and median follow-up is longer (4.1 years) than most. Late relapses and disease-related deaths after 5 years are also reported in long-term follow-up of PVB (cisplatin, vinblastine, bleomycin) treated patients from Indiana University (Greist et al., 1985) . Most of our late deaths were tumour-related although intercurrent causes were seen as well as one fatality from probable treatmentinduced leukaemia. When we analysed these patients we found that reduced rates of drug delivery during first-line therapy were associated with subsequent relapse (Crawford et al., 1988) . Hence, intensifying frequency of drug administration in conventional dose regimens is a potential method for improving survival among adverse prognosis patients without resorting to high dose chemotherapy and subjecting the patients to its extra toxicity.
Treatment results in adverse prognosis NSGCT must be interpreted critically for the method of reporting results (response rates rather than overall survival) as well as duration of follow-up. Encouraging early results with new and more toxic treatment regimens in advanced disease categories may yield no better long-term outcome than conventional therapies. Improved response rate and survival in NSGCT have been demonstrated in a randomised study with combination chemotherapy using DDP doses of 120mgm-2 opposed to 75mgm-2 (Samson et al., 1984) . The use of ultra-high dose DDP (175-200mgm-2 per course) and VP16 regimens cause significant numbers of toxic deaths (Ozols, 1987; Schmoll et al., 1987) and survival actually appears worse than the results with POMB/ACE (120mgm 2 DDP per course) (see Table IV ). The results of Pizzocaro et al. (1985) with conventional doses of DDP and VP16 are similar to our own. Bosl et al. (1983) performed a multivariate analysis of prognostic variables which identified the concentration of lactate dehydrogenase, hCG and the total number of metastases as the major adverse prognostic variables. They used these variables to identify a group of patients who received alternating chemotherapy in an attempt to improve their survival. However, although this was not a randomised comparison there was no improvement in the results with their approach (Bosl et al., 1987) . More recently the same group have performed a parallel analysis to that reported here (Bajorin et al., 1988) . In a smaller series of patients with a shorter follow-up they have also identified the limitations of current staging classifications. They found that there were differences in sensitivity, specificity and predictive value in the classifications they analysed. They included two systems analysed in this report (IND and EORTC) and also reported on their own system (Memorial Sloan-Kettering Cancer Center (MSKCC)) and the National Cancer Institute (NCI) systems. We agree with their conclusions that randomised trials with agreed eligibility criteria for entry will be required before conclusions on the relative efficacy of different regimens of chemotherapy can be made.
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